Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial
Top Cited Papers
Open Access
- 14 April 2026
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1865-1870
Abstract
A small azobenzene photoswitch molecule (KIO-301), designed to confer light responsiveness to retinal ganglion cells, was evaluated for safety and feasibility in a first-in-human, phase 1, gene-agnostic, open-label, dose-escalation clinical trial in individuals with advanced retinitis pigmentosa (RP). KIO-301 was administered by intravitreal injection to 12 eyes of 6 participants. The primary outcome was ocular and systemic safety over 30 days. Secondary and exploratory assessments included functional vision testing, visual acuity, kinetic visual field, functional magnetic resonance imaging and participant-reported outcomes. The primary safety outcome was met, with no serious adverse events or dose-limiting toxicities observed at any point. No drug-related intraocular inflammation occurred, and all ocular adverse events were mild and procedure-related. Exploratory assessments identified variation in light perception and functional vision measures in some participants. Light-evoked blood-oxygen-level-dependent signal changes in visual cortical regions were observed following dosing and showed a temporal pattern compatible with pharmacodynamic activity. Participant-reported quality-of-life scores varied over time. In this small, nonrandomized phase 1 study in individuals with late-stage RP, intravitreal KIO-301 demonstrated an acceptable safety and tolerability profile, supporting the feasibility of photoswitch therapy in advanced RP, and motivating further evaluation in larger trials. ClinicalTrials.gov identifier: NCT05282953Keywords
All Related Versions
Funding Information
- Kiora Pharmaceuticals, Inc.
- Kiora Pharmaceuticals
This publication has 22 references indexed in Scilit:
- RetiGene, a comprehensive gene atlas for inherited retinal diseasesThe American Journal of Human Genetics, 2025
- Purinergic P2X7 receptor involves in anti-retinal photodamage effects of berberinePurinergic Signalling, 2024
- The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: A systematic reviewGenetics in Medicine, 2022
- Photoswitchable LipidsChemBioChem, 2020
- Restoring Vision to the Blind with Chemical PhotoswitchesChemical Reviews, 2018
- How Azobenzene Photoswitches Restore Visual Responses to the Blind RetinaNeuron, 2016
- Restoring Visual Function to Blind Mice with a Photoswitch that Exploits Electrophysiological Remodeling of Retinal Ganglion CellsNeuron, 2014
- Development of the 25-list-item National Eye Institute Visual Function QuestionnaireArchives of Ophthalmology (1950), 2001
- Morphometric Analysis of Macular Photoreceptors and Ganglion Cells in Retinas With Retinitis PigmentosaArchives of Ophthalmology (1950), 1992
- Prevalence of Retinitis Pigmentosa in MaineAmerican Journal of Ophthalmology, 1984